About the Company
Schematic illustration of Intervacc's technology platform with Strangvac® as an example.
1) TARGET IDENTIFICATION Surface proteins from S. equi, which are responsible for adhesion to tissue surfaces, are identified.
2) DNA FRAGMENTS ARE CREATED Genes from selected surface proteins are fused to a composite DNA fragment and cloned in E. coli.
3) ANTIGENS ARE PRODUCED The composite DNA fragment is used to produce antigens on a large scale.
4) VACCINE PRODUCTION The purification process of the antigens is scaled up and optimized.
5) VACCINATION Strangvac® is administered to the horse in order to stimulate the immune system.
6) IMMUNE RESPONSE The horse forms antibodies that recognize S. equi. and thus slows down the course of the infection.
Also in the pipeline is our second vaccine Piggivac™ against S. suis infection in pigs – one of the most common and serious diseases currently treated with antibiotics. Read more about Piggivac™ here »
Intervacc meets future
needs in animal health
Intervacc is a Swedish publicly quoted growth company developing innovative animal vaccines, which are marketed and sold in synergy with a growing portfolio of veterinary medicines.
Founded in 2001 and listed on the stock exchange in 2017, Intervacc has its roots in many years of research at Karolinska Institutet and the Swedish University of Agricultural Sciences. The company is responsible for the entire value chain, from research and development of veterinary vaccines to marketing, sales and customer support.
The global market for animal vaccines is growing, and the company’s technology platform and sales capacity for next-generation vaccines provide strong opportunities to gain new market share.
A broader offering for veterinarians
Intervacc also brings together diagnostics operations and the distribution of a broad range of veterinary medicines and vaccines, creating a strong and integrated platform for veterinarians.
Strangvac® – a milestone for Intervacc
Our first self-developed and approved vaccine, Strangvac®, is the world's first vaccine, based on recombinant proteins, against strangles. With this in its portfolio, Intervacc has established itself as a leading innovator in veterinary medicine.
The initial and registration-enabling studies with Strangvac® in the American market commenced in late 2025. Read more about Strangvac® and strangles here »
At the same time, we continue to develop new vaccines that meet future needs in animal health. Also in the pipeline is our vaccine candidate Piggivac™ against S. suis infection in pigs. The vaccine candidate is now being prepared for GMP manufacturing and registration-enabling clinical studies. Read more about Piggivac™ and S. suis infection here »
Additional products in the range
In addition to self-developed vaccines, Intervacc has a growing business in high-quality veterinary medicines and vaccines – for both companion and farm animals. Read more here »
These agency products for horses, pigs, cattle, sheep, poultry, dogs, and cats are sold in the Scandinavian markets. The product portfolio has clear synergies with the vaccines developed internally within the company.
Intervacc's diagnostic laboratory
Our accredited and renowned laboratory offers services in the Swedish market for veterinary diagnostics in bacteriology and mycology. Read more here »
A strong team with solid experience in animal health
Intervacc possesses collective specialist expertise that has enabled the development of a vaccine protecting against strangles. The management and board have extensive experience in business operations and, not least, research in microbiology, infection biology, and genetic engineering. Today, the company employs staff with long experience in research, production, marketing, and sales.
The sale of Strangvac® in Scandinavia is handled by the company's own sales organization, while sales in the rest of Europe are managed by partner Dechra.
OPERATIONS
THE COMPANY
Schematic illustration of Intervacc's technology platform with Strangvac® as an example.
1) TARGET IDENTIFICATION Surface proteins from S. equi, which are responsible for adhesion to tissue surfaces, are identified.
2) DNA FRAGMENTS ARE CREATED Genes from selected surface proteins are fused to a composite DNA fragment and cloned in E. coli.
3) ANTIGENS ARE PRODUCED The composite DNA fragment is used to produce antigens on a large scale.
4) VACCINE PRODUCTION The purification process of the antigens is scaled up and optimized.
5) VACCINATION Strangvac® is administered to the horse in order to stimulate the immune system.
6) IMMUNE RESPONSE The horse forms antibodies that recognize S. equi. and thus slows down the course of the infection.
Intervacc meets future needs in animal health
Intervacc is a Swedish listed biotechnology company that develops, markets, and sells innovative vaccines for animals.
With a modern technology platform based on research at Karolinska Institutet and the Swedish University of Agricultural Sciences – and with a clear focus on preventive healthcare – the ambition is to contribute to improved animal welfare and a more sustainable use of antibiotics.
The company is responsible for the entire value chain – from research and development to marketing, sales, and customer support. Intervacc also encompasses diagnostic operations and a wide range of veterinary medicines and vaccines, creating a strong and cohesive platform for veterinarians.
The market for animal vaccines is growing globally and our technology platform and sales capacity for next-generation vaccines provide us with significant opportunities to gain new market shares.
Our first self-developed and approved vaccine, Strangvac®, is the world's first vaccine, based on recombinant proteins, against strangles. With this in its portfolio, Intervacc has established itself as a leading innovator in veterinary medicine. At the same time, we continue to develop new vaccines that meet future needs in animal health.
Also in the pipeline is our second vaccine Piggivac™ against S. suis infection in pigs – one of the most common and serious diseases currently treated with antibiotics.
With a modern technology platform based on research at Karolinska Institutet and the Swedish University of Agricultural Sciences – and with a clear focus on preventive healthcare – the ambition is to contribute to improved animal welfare and a more sustainable use of antibiotics.
The company is responsible for the entire value chain – from research and development to marketing, sales, and customer support. Intervacc also encompasses diagnostic operations and a wide range of veterinary medicines and vaccines, creating a strong and cohesive platform for veterinarians.
The market for animal vaccines is growing globally and our technology platform and sales capacity for next-generation vaccines provide us with significant opportunities to gain new market shares.
Our first self-developed and approved vaccine, Strangvac®, is the world's first vaccine, based on recombinant proteins, against strangles. With this in its portfolio, Intervacc has established itself as a leading innovator in veterinary medicine. At the same time, we continue to develop new vaccines that meet future needs in animal health.
Strangvac® – a modern
multi-component vaccine
Strangvac® is developed to protect against the contagious and painful bacterial disease strangles. It is based on recombinant proteins (harmless parts of the bacterium) instead of live or completely inactivated streptococcal bacteria, Streptococcus equi. Strangvac® contains recombinant protein antigens from Streptococcus equi. They are not live and cannot spread to other animals. For approved indication and full product information, see FASS Vet.
On August 16, 2021, the EU Commission granted a marketing authorization for Strangvac®, making it the first Swedish animal health vaccine to be approved via EMA's central procedure, which covers all member states of the European Union. Strangvac® has also been granted marketing authorization in the United Kingdom.
Clinical studies are currently being conducted in the USA, and we are seeking a distributor for the American market who is ready for registration and launch there.
Innovative technology creates new opportunities
The vaccine is developed with innovative technology based on fused recombinant proteins. The research underpinning the vaccine's technical platform has been conducted in collaboration with researchers at Karolinska Institutet and the Swedish University of Agricultural Sciences, SLU.
The marketing authorization is based on the results of a series of clinical trials that studied Strangvac®'s safety, immune response, efficacy, and ability to differentiate vaccinated from infected horses (DIVA compatibility).
Strangles – one of the oldest equine diseases
The contagious respiratory disease strangles is one of the oldest known diseases in horses. The disease affects horses worldwide, and in Sweden, one to two strangles outbreaks occur every week, often linked to the import of infected horses.
Horses can be carriers for a very long time, even after symptoms have disappeared. A Swedish research study at SVA (H1147203) showed that as many as 92% of examined horses remained persistent carriers after a standard three-week isolation. The same study showed that 67% remained carriers even after six weeks of isolation if not properly tested.
Increase in strangles globally
Globally, strangles is classified as one of the most common and widespread infectious diseases in horses, and the number of strangles cases is increasing. The disease is endemic in almost the entire world and constitutes a major economic and animal welfare problem.
In Sweden, around 60 outbreaks (stables – not individuals) are reported annually, and in the UK, approximately 1,000. In Sweden, strangles is a notifiable disease to the Swedish Board of Agriculture – however, this differs between countries globally.
In addition to the suffering of affected horses, an outbreak entails significant economic consequences. An affected stable or riding school needs to take extensive restrictive measures to prevent further infection, which also includes closing operations for sanitation and keeping horses in quarantine.
STRANGVAC® & STRANGLES
This is strangles
Symptoms and treatment
Classic symptoms of strangles include high fever, yellow purulent nasal discharge, and swollen, painful lymph nodes in the head and neck that can develop into abscesses. The disease is caused by streptococcal bacteria and varies greatly in severity between individuals.
Treatment is assessed by a veterinarian based on the disease phase and the horse's condition. Antibiotics are used in specific cases, while supportive care, isolation, and infection control measures are often central.
Mature abscesses under the jaw may need to be opened and drained by a veterinarian to relieve pressure.
Sequelae and complications
Mortality from strangles is usually below 2% in uncomplicated cases but can rise to 8–10% if serious complications occur. Sequelae and complications are relatively common, affecting up to 20% of infected horses.
» Bastard strangles: The bacteria spread via blood or lymph and form abscesses in internal organs such as the lungs, liver, spleen, or brain. Bastard strangles is one of the most common causes of death or euthanasia.
» Anasarca (Purpura haemorrhagica): A severe, immune-mediated inflammation of the blood vessels (vasculitis). It causes severe, painful swelling in the legs and head, as well as bleeding in the mucous membranes. The condition has high mortality if not treated promptly.
» Guttural pouch empyema and chondroids
(concretions): Pus accumulates in the horse's guttural pouches and can dry into hard "stones" (chondroids). This makes the horse a chronic, silent carrier that may require surgery.
» Airway obstruction: Extremely swollen lymph nodes can press on the trachea and pharynx. This leads to acute respiratory distress (hence the English name strangles).
» Muscle inflammation and emaciation: Some horses suffer from immune-mediated muscle atrophy or myocarditis.
The company currently owns 5 published patent families. These published patent families collectively include approximately 20 granted patents in force in various countries and several additional pending patent applications.
The primary purpose of the submitted patent applications is related to protecting the company's vaccine product Strangvac®.
In addition, the applications also describe the possibility of developing vaccine products to protect against diseases caused by Streptococcus zooepidemicus. The application documents thoroughly describe the various vaccine components, as well as their production and administration methods. Furthermore, the documents also contain examples where different combinations of vaccine formulations have been tested in animal studies, in both mice and horses.
The company has also registered the trademark for the Strangvac® vaccine and had it approved as a medicinal product name.
The company currently owns 5 published patent families. These published patent families collectively include approximately 20 granted patents in force in various countries and several additional pending patent applications.
The primary purpose of the submitted patent applications is related to protecting the company's vaccine product Strangvac®.
In addition, the applications also describe the possibility of developing vaccine products to protect against diseases caused by Streptococcus zooepidemicus. The application documents thoroughly describe the various vaccine components, as well as their production and administration methods. Furthermore, the documents also contain examples where different combinations of vaccine formulations have been tested in animal studies, in both mice and horses.
The company has also registered the trademark for the Strangvac® vaccine and had it approved as a medicinal product name.
PATENTS
THE FIVE PUBLISHED PATENT FAMILIES ARE:
» Trivac, WO 2004/032957 A1, (priority 2002).
The patent has been granted and is valid in the USA until 2028.
» Penta/Septavacc, WO 2009/075646 A1, (priority 2007).
Patents have been granted and are valid in Europe until 2028 and the USA until 2031.
» Strangvac®, WO 2011/149419 A1, (priority 2010)
Patents have been granted and are in force in Europe, the USA (US 9,795,664), Hong Kong, China, and Australia until 2031, with additional SPC protection granted or pending in Europe until 2036.
» S. suis vaccine, WO 2017/005913 A1, (priority 2015)
Patent granted in the USA (US 11,155,585) and application is pending in Europe.
» S. suis vaccine, WO 2023/203238 A1, (priority 2023).
Application is pending in Europe, the USA, Canada, and China.
Piggivac™
– vaccine candidate against S. suis
Piggivac™ – or INV274 as the project name – is our development project for a vaccine against Streptococcus suis infection in pigs. The vaccine candidate is based on recombinant proteins, and the next development step includes preparations for GMP manufacturing and registration-enabling clinical studies.
Streptococcus suis is an important global endemic swine pathogen causing meningitis, sepsis, arthritis, and endocarditis in weaned piglets between 4 and 10 weeks of age. Mortality can be as high as 20% on some farms, and the total cost of S. suis infection in pigs is estimated at more than 250 million euros annually in Europe alone. Reports from the field (Vaccine, article no. 127077) show an increasing number of S. suis infections. This has created a great need for a functional vaccine, as commercial alternatives are lacking.
S. suis serotype 2 is the globally most common cause of severe disease in piglets. Serotype 9 is, currently, less common than serotype 2 but is increasingly a cause of severe disease in pigs in Europe. Protection against multiple S. suis serotypes has been requested by the pig farming industry for many years.
Intervacc is the first and so far only company in the world to demonstrate – in two separate studies – that piglets are protected against the virulent and severely pathogenic S. suis sequence types 1 and 16 (serotype 2 and 9 respectively) by vaccinating sows that transfer immunity to the piglets.
The results represent an important step in the continued development of the vaccine candidate, as the strains used in the studies are not closely related and the vaccine was only administered to pregnant sows with transfer of immunity to the piglets.
Reduced need for antibiotics and improved profitability for pig farmers
It is estimated that S. suis accounts for one third of the total antibiotic use in weaned pigs. A safe and effective vaccine against S. suis would reduce the need for antibiotics and the global threat from antibiotic resistance, playing a significant role in improving animal welfare and enhancing profitability in the pig farming industry.
The INV274 (Piggivac™) project has, in fierce competition, been awarded funding via the Eurostars-2 program. The project phase for which Intervacc, together with Moredun Scientific in Edinburgh, has now been granted funding includes resources to carry out several important development steps, including preclinical efficacy studies in piglets, antibody analyses, and vaccination of pregnant sows.
PIGGIVAC™ & S. SUIS-INFECTION
This is S. suis infection
Symptoms and treatment
In pigs, Streptococcus suis
primarily causes meningitis, arthritis, and sudden deaths. It most often affects weaned piglets up to 10 weeks of age.
In humans, the infection causes high fever, neck stiffness, severe headache, confusion, and hearing loss.
The infection is acutely treated with intravenous antibiotics, usually penicillin or ampicillin. In large outbreaks, antibiotics can be administered via drinking water or feed.
The company currently owns 5 published patent families. These published patent families collectively include approximately 20 granted patents in force in various countries and several additional pending patent applications.
The primary purpose of the submitted patent applications is related to protecting the company's vaccine product Strangvac®.
In addition, the applications also describe the possibility of developing vaccine products to protect against diseases caused by Streptococcus zooepidemicus. The application documents thoroughly describe the various vaccine components, as well as their production and administration methods. Furthermore, the documents also contain examples where different combinations of vaccine formulations have been tested in animal studies, in both mice and horses.
The company has also registered the trademark for the Strangvac® vaccine and had it approved as a medicinal product name.
PATENTS
THE FIVE PUBLISHED PATENT FAMILIES ARE:
» Trivac, WO 2004/032957 A1, (priority 2002).
The patent has been granted and is valid in the USA until 2028.
» Penta/Septavacc, WO 2009/075646 A1, (priority 2007).
Patents have been granted and are valid in Europe until 2028 and the USA until 2031.
» Strangvac®, WO 2011/149419 A1, (priority 2010)
Patents have been granted and are in force in Europe, the USA (US 9,795,664), Hong Kong, China, and Australia until 2031, with additional SPC protection granted or pending in Europe until 2036.
» S. suis vaccine, WO 2017/005913 A1, (priority 2015)
Patent granted in the USA (US 11,155,585) and application is pending in Europe.
» S. suis vaccine, WO 2023/203238 A1, (priority 2023).
Application is pending in Europe, the USA, Canada, and China.
Carl-Johan Dalsgaard
Chief Executive Officer
Dr. Dalsgaard holds a medical degree and a PhD from Karolinska Institutet, and a postdoctoral degree from Harvard Medical School. He has 10 years of experience in leading research and development positions and was part of the company's research and
development management at AstraZeneca. He has published more than 80 scientific articles in scientific journals and holds more than 40 granted patents. Carl-Johan has been a venture partner at HealthCap since 2000 and CEO of companies in which HealthCap has invested. Most recently, he carried out a turnaround of Vicore (publ.), was startup CEO at Small Therapeutics before joining Intervacc as CEO in February 2026.
Shareholding: 900,000
Commencement of service: 2026
Jan Persson
Chief Financial Officer
Jan holds a Master of Science in Business and Economics from Stockholm University and has many years of experience as an operational and business-oriented CFO before joining Intervacc in 2019. He has broad experience from a variety of diverse industries including high-tech products, auditing, fashion, music, and a business organization.
Jan has also held other leading positions, including Head of Project Management, responsible for sales in international companies with a Swedish base, and has started several businesses abroad.
Shareholding: 1,251,251
Commencement of service: 2020
MANAGEMENT
Diverse expertise
– with a shared
commitment to
animal health
With broad experience in research, pharmaceutical development, business development, and commercialization, Intervacc's management combines expertise all the way from science to market.
Together, we work to translate scientific advancements into innovative solutions that create value for veterinarians, animals, animal owners, and society at large.
With a focus on quality, long-term perspective, and sustainable growth, the management leads the company's strategic development and ensures close interaction between research, product development, marketing, and sales.
Anna-Carin Lagerlöf
Head of Sales and Marketing
Bachelor of Science in Business and Economics
with a specialization in marketing, Örebro University. Anna-Carin has over 20 years of experience in leading positions at global pharmaceutical companies such as Pharmacia, Novartis, Abbott, and AbbVie. Before Anna-Carin joined Intervacc in 2025, she held a position as Country Manager for the Nordics at IDEXX Laboratories, where she built up the Nordic operations from approximately 100 to 500 million SEK in sales. With solid experience in business development, sales, marketing, and leadership, she is responsible for strengthening the company's market position and developing global demand for Strangvac®.
Shareholding: 530,000
Commencement of service: 2025
Carl-Johan Dalsgaard
Chief Executive Officer
Dr. Dalsgaard holds a medical degree and a PhD from Karolinska Institutet, and a postdoctoral degree from Harvard Medical School. He has 10 years of experience in leading research and development positions and was part of the company's research and
development management at AstraZeneca. He has published more than 80 scientific articles in scientific journals and holds more than 40 granted patents. Carl-Johan has been a venture partner at HealthCap since 2000 and CEO of companies in which HealthCap has invested. Most recently, he carried out a turnaround of Vicore (publ.), was startup CEO at Small Therapeutics before joining Intervacc as CEO in February 2026.
Shareholding: 900,000
Commencement of service: 2026
Jan Persson
Chief Financial Officer
Master of Science in Business and Economics, Stockholm University
Shareholding: 1,251,251
Commencement of service: 2020
MANAGEMENT
Diverse expertise
– with a shared
commitment to
animal health
With broad experience in research, pharmaceutical development, business development, and commercialization, Intervacc's management combines expertise all the way from science to market.
Together, we work to translate scientific advancements into innovative solutions that create value for veterinarians, animals, animal owners, and society at large.
With a focus on quality, long-term perspective, and sustainable growth, the management leads the company's strategic development and ensures close interaction between research, product development, marketing, and sales.
Anna-Carin Lagerlöf
Head of Sales and Marketing
Bachelor of Science in Business and Economics
with a specialization in marketing, Örebro University. Anna-Carin has over 20 years of experience in leading positions at global pharmaceutical companies such as Pharmacia, Novartis, Abbott, and AbbVie. Before Anna-Carin joined Intervacc in 2025, she held a position as Country Manager for the Nordics at IDEXX Laboratories, where she built up the Nordic operations from approximately 100 to 500 million SEK in sales. With solid experience in business development, sales, marketing, and leadership, she is responsible for strengthening the company's market position and developing global demand for Strangvac®.
Shareholding: 475,347
Commencement of service: 2025
Carl-Johan Dalsgaard
Chief Executive Officer
Dr. Dalsgaard holds a medical degree and a PhD from Karolinska Institutet, and a postdoctoral degree from Harvard Medical School. He has 10 years of experience in leading research and development positions and was part of the company's research and
development management at AstraZeneca. He has published more than 80 scientific articles in scientific journals and holds more than 40 granted patents. Carl-Johan has been a venture partner at HealthCap since 2000 and CEO of companies in which HealthCap has invested. Most recently, he carried out a turnaround of Vicore (publ.), was startup CEO at Small Therapeutics before joining Intervacc as CEO in February 2026.
Shareholding: 900,000
Commencement of service: 2026
Jan Persson
Chief Financial Officer
Master of Science in Business and Economics, Stockholm University
Shareholding: 1,251,251
Commencement of service: 2020
MANAGEMENT
Diverse expertise
– with a shared
commitment to
animal health
With broad experience in research, pharmaceutical development, business development, and commercialization, Intervacc's management combines expertise all the way from science to market.
Together, we work to translate scientific advancements into innovative solutions that create value for veterinarians, animals, animal owners, and society at large.
With a focus on quality, long-term perspective, and sustainable growth, the management leads the company's strategic development and ensures close interaction between research, product development, marketing, and sales.
Anna-Carin Lagerlöf
Head of Sales and Marketing
Bachelor of Science in Business and Economics
with a specialization in marketing, Örebro University. Anna-Carin has over 20 years of experience in leading positions at global pharmaceutical companies such as Pharmacia, Novartis, Abbott, and AbbVie. Before Anna-Carin joined Intervacc in 2025, she held a position as Country Manager for the Nordics at IDEXX Laboratories, where she built up the Nordic operations from approximately 100 to 500 million SEK in sales. With solid experience in business development, sales, marketing, and leadership, she is responsible for strengthening the company's market position and developing global demand for Strangvac®.
Shareholding: 475,347
Commencement of service: 2025
Andrew Waller
Chief Scientific Officer
Dr Waller received his PhD from
the University of York and has over 12 years of experience in leading research and development positions in the pharmaceutical industry at British Biotech and Intervacc AB. He led the bacteriological research program at the Animal Health Trust for 17 years, has published more than 110 peer-reviewed scientific articles, is the inventor of eight patents, and is recognized as one of the world leaders in the field of streptococcal infections in animals. Andrew has been a member of the scientific advisory committee for the Petplan Charitable Trust for over 17 years and has previously won the Sir Colin Spedding and British Horse Society Equine Welfare Awards for his work in improving equine health.
Shareholding: 4,200
Date of appointment: 2020
Astrid Larberg
Program Manager
Veterinarian with a PhD from Copenhagen University. Astrid has extensive experience in several areas within the life science sector. Since joining Intervacc, she has advanced through several leading positions, including Quality Manager, Head of Technical Operations, and Program Manager. In these roles, she has led external manufacturing networks and vaccine development initiatives, including the US development program for Strangvac.
Before Astrid joined Intervacc in 2021, she held positions at AstraZeneca and worked in both clinical veterinary medicine and public health within veterinary medicine. Her scientific background includes research in antimicrobial stewardship and antibiotic resistance, with international collaborations in academia and industry.
Shareholding: 222,067
Date of appointment: 2026
Lars Stubberud
Chief Technical Officer
Lars Stubberud holds a Master's degree (candidatus pharmaciae) and a PhD in pharmaceutical science from the University of Oslo. He has more than 30 years of experience in the pharmaceutical industry within the broader field of CMC, including formulation science, product development, technology transfer/technical management, as well as regulatory affairs and quality assurance. Before joining Intervacc in 2026, Lars held various positions and leadership roles at Nycomed AS, AstraZeneca, as well as Cubist Pharmaceuticals GmbH, Biogen International GmbH, and Alexion Pharma GmbH. Most recently, Lars comes from Calliditas Therapeutics AB.
Shareholding: 184,300
Date of appointment: 2026
Andrew Waller
Chief Scientific Officer
Dr Waller received his PhD from
the University of York and has over 12 years of experience in leading research and development positions in the pharmaceutical industry at British Biotech and Intervacc AB. He led the bacteriological research program at the Animal Health Trust for 17 years, has published more than 110 peer-reviewed scientific articles, is the inventor of eight patents, and is recognized as one of the world leaders in the field of streptococcal infections in animals. Andrew has been a member of the scientific advisory committee for the Petplan Charitable Trust for over 17 years and has previously won the Sir Colin Spedding and British Horse Society Equine Welfare Awards for his work in improving equine health.
Shareholding: 4,200
Date of appointment: 2020
Astrid Larberg
Program Manager
Veterinarian with a PhD from the University of Copenhagen. Astrid has extensive experience in several areas within the life science sector. Since joining Intervacc, she has advanced through several leading positions, including Quality Manager, Head of Technical Operations, and Program Manager. In these roles, she has led external manufacturing networks and vaccine development initiatives, including the US development program for Strangvac. Before Intervacc, Astrid held positions at AstraZeneca and worked in both clinical veterinary medicine and veterinary public health. Her scientific background includes research in antimicrobial stewardship and antibiotic resistance, with international collaborations in academia and industry.
Shareholding: 20,832
Date of appointment: 2021
Lars Stubberud
Chief Technical Officer
Lars Stubberud holds a Master's degree (candidatus pharmaciae) and a PhD in pharmaceutical science from the University of Oslo. He has more than 30 years of experience in the pharmaceutical industry within the broader field of CMC, including formulation science, product development, technology transfer/technical management, as well as regulatory affairs and quality assurance. Before joining Intervacc in 2026, Lars held various positions and leadership roles at Nycomed AS, AstraZeneca, as well as Cubist Pharmaceuticals GmbH, Biogen International GmbH, and Alexion Pharma GmbH. Most recently, Lars comes from Calliditas Therapeutics AB.
Shareholding: 0
Date of appointment: 2026
Andrew Waller
Chief Scientific Officer
Dr Waller received his PhD from
the University of York and has over 12 years of experience in leading research and development positions in the pharmaceutical industry at British Biotech and Intervacc AB. He led the bacteriological research program at the Animal Health Trust for 17 years, has published more than 110 peer-reviewed scientific articles, is the inventor of eight patents, and is recognized as one of the world leaders in the field of streptococcal infections in animals. Andrew has been a member of the scientific advisory committee for the Petplan Charitable Trust for over 17 years and has previously won the Sir Colin Spedding and British Horse Society Equine Welfare Awards for his work in improving equine health.
Shareholding: 4,200
Date of appointment: 2020
Astrid Larberg
Program Manager
Veterinarian with a PhD from the University of Copenhagen. Astrid has extensive experience in several areas within the life science sector. Since joining Intervacc, she has advanced through several leading positions, including Quality Manager, Head of Technical Operations, and Program Manager. In these roles, she has led external manufacturing networks and vaccine development initiatives, including the US development program for Strangvac. Before Intervacc, Astrid held positions at AstraZeneca and worked in both clinical veterinary medicine and veterinary public health. Her scientific background includes research in antimicrobial stewardship and antibiotic resistance, with international collaborations in academia and industry.
Shareholding: 20,832
Date of appointment: 2021
Lars Stubberud
Chief Technical Officer
Lars Stubberud holds a Master's degree (candidatus pharmaciae) and a PhD in pharmaceutical science from the University of Oslo. He has more than 30 years of experience in the pharmaceutical industry within the broader field of CMC, including formulation science, product development, technology transfer/technical management, as well as regulatory affairs and quality assurance. Before joining Intervacc in 2026, Lars held various positions and leadership roles at Nycomed AS, AstraZeneca, as well as Cubist Pharmaceuticals GmbH, Biogen International GmbH, and Alexion Pharma GmbH. Most recently, Lars comes from Calliditas Therapeutics AB.
Shareholding: 0
Date of appointment: 2026
Emil Billbäck
Chairman
More than 25 years of experience in the Life Science industry, including 11 years in leading positions under private equity ownership. Emil was previously CEO of Bonesupport AB, a leading company in orthobiologics, bone healing, and infection treatment. He also holds other board assignments, including in Xvivo and Bonesupport.
Independent in relation to the Company and its senior executives. Independent in relation to major shareholders.
Shareholding: 2,429,008
Member since: 2024
Chairman since: 2026
Håkan Björklund
Member
Former Chairman of Intervacc, SOBI, QIAGEN, and Lundbeck. Med. Dr and Associate Professor from KI with extensive experience in leading positions within the Life Science industry as CEO of Nycomed, as well as Head of Research at Pharmacia, Head of Ophthalmics at Astra Draco, and in the commercial sector as Head of Northern Europe at Astra. Håkan has held or currently holds other board assignments in both public and private companies, including ATOS and Bonesupport.
Independent in relation to the Company and its senior executives. Independent in relation to major shareholders.
Shareholding: 8,312,158
Member since: 2023
THE BOARD
Collective competence
that creates value
With solid experience from Life Science, research, pharmaceutical development, communication, finance, and commercialization, the board provides strategic support for Intervacc's continued development.
Together, the members contribute perspectives and experiences that strengthen the company's ability to develop, commercialize, and create long-term value around innovative vaccines.
Lisen Bratt Fredricson
Member
Olympic show jumper and one of Sweden's most prominent equestrian profiles, active as an entrepreneur in the equestrian sport. Co-founder of Swedish Showjumping Horse Sales and Ryttargalan. Lisen runs Grevlundagården with her husband Peder Fredricson, she is a co-owner of Scandinavian Horse Event Production AB, Jönköping Horse Show, and the online store Get the Gallop. Contributes insights into the needs, challenges, and conditions of the equestrian industry.
Independent in relation to the Company and its senior executives. Independent in relation to major shareholders.
Shareholding: 150,000
Member since: 2023
Emil Billbäck
Chairman
More than 25 years of experience in Life
Science industry, including
11 years in leading positions
under private equity ownership.
Emil was previously CEO of
Bonesupport AB, a leading
company in orthobiologics,
bone healing, and infection treatment. He also holds other
board assignments, including in
Xvivo and Bonesupport.
Independent in relation to the Company and its senior executives. Independent in relation to major shareholders.
Shareholding: 2,429,008
Member since: 2024
Håkan Björklund
Member
Former Chairman of SOBI,
QIAGEN, and Lundbeck. Med. Dr
and Associate Professor from KI with extensive experience in leading positions within the Life Science industry as CEO of Nycomed, as well as Head of Research at Pharmacia, Head of Ophthalmics at Astra Draco, and in the commercial sector as Head of Northern Europe at Astra. Håkan has held or currently holds other board assignments in both public and private companies, including ATOS and Bonesupport.
Independent in relation to the Company and its senior executives.
Independent in relation to major shareholders.
Shareholding: 8,312,158
Member since: 2023
THE BOARD
Collective competence
that creates value
With solid experience from Life Science, research, pharmaceutical development, communication, finance, and commercialization, the board provides strategic support for Intervacc's continued development.
Together, the members contribute perspectives and experiences that strengthen the company's ability to develop, commercialize, and create long-term value around innovative vaccines.
Lisen Bratt Fredricson
Member
Olympic show jumper and one of
Sweden's most prominent equestrian profiles, active as an entrepreneur in the equestrian sport. Co-founder of Swedish Showjumping Horse Sales and Ryttargalan. Lisen runs Grevlundagården with her husband Peder Fredricson, she is a co-owner of Scandinavian Horse Event Production AB, Jönköping Horse Show, and the online store Get the Gallop. Contributes insights into the needs, challenges, and conditions of the equestrian industry.
Independent in relation to the Company and its senior executives. Independent in relation to major shareholders.
Shareholding: 150,000
Member since: 2023
Emil Billbäck
Chairman
More than 25 years of experience in Life
Science industry, including
11 years in leading positions
under private equity ownership.
Emil was previously CEO of
Bonesupport AB, a leading
company in orthobiologics,
bone healing, and infection treatment. He also holds other
board assignments, including in
Xvivo and Bonesupport.
Independent in relation to the Company and its senior executives. Independent in relation to major shareholders.
Shareholding: 2,429,008
Member since: 2024
Håkan Björklund
Member
Former Chairman of SOBI,
QIAGEN, and Lundbeck. Med. Dr
and Associate Professor from KI with extensive experience in leading positions within the Life Science industry as CEO of Nycomed, as well as Head of Research at Pharmacia, Head of Ophthalmics at Astra Draco, and in the commercial sector as Head of Northern Europe at Astra. Håkan has held or currently holds other board assignments in both public and private companies, including ATOS and Bonesupport.
Independent in relation to the Company and its senior executives.
Independent in relation to major shareholders.
Shareholding: 8,312,158
Member since: 2023
THE BOARD
Collective competence
that creates value
With solid experience from Life Science, research, pharmaceutical development, communication, finance, and commercialization, the board provides strategic support for Intervacc's continued development.
Together, the members contribute perspectives and experiences that strengthen the company's ability to develop, commercialize, and create long-term value around innovative vaccines.
Lisen Bratt Fredricson
Member
Olympic show jumper and one of
Sweden's most prominent equestrian profiles, active as an entrepreneur in the equestrian sport. Co-founder of Swedish Showjumping Horse Sales and Ryttargalan. Lisen runs Grevlundagården with her husband Peder Fredricson, she is a co-owner of Scandinavian Horse Event Production AB, Jönköping Horse Show, and the online store Get the Gallop. Contributes insights into the needs, challenges, and conditions of the equestrian industry.
Independent in relation to the Company and its senior executives. Independent in relation to major shareholders.
Shareholding: 150,000
Member since: 2023
Lennart Johansson
Member
MBA from the Stockholm School of Economics with extensive experience from leading positions at Atlas Copco and Investor (2006-2015). Previous board assignments: Gambro, Mölnlycke, Lindorff, SAAB, Hi3G, SOBI, and a number of unlisted Life Science companies. Lennart also holds board assignments in Bonesupport, Chalmers Ventures, GoCo Development, and is a Senior Advisor to Patricia Industries.
Independent in relation to the Company and its senior executives. Independent in relation to major shareholders.
Shareholding: 2,140,246
Member since: 2023
Björn Odlander
Member
Founder and managing partner at HealthCap. Björn previously conducted research in biochemistry focusing on inflammation at Karolinska Institutet and was Head of the Health Care Equity Research Team at ABB Aros Securities. During his time at ABB Aros Securities, Björn also advised the management of several major pharmaceutical and medical technology companies. Björn has extensive experience from numerous board assignments in listed and unlisted companies within the Life Science sector, including Q-Med AB, NicOx SA, Jerini AG, and Bonesupport.
Dependent in relation to the Company and its senior executives. Dependent in relation to major shareholders.
Shareholding: 0
Member since: 2025
Camilla Ramfelt McCarthy
Member
Marketing strategist and
business developer with extensive
experience in brand development and strengthening companies' market position, visibility, and growth through business-driven communication. Previously CEO and Creative Director at Ramfelt McCarthy advertising agency, and founder and editor-in-chief of the equestrian magazine Equipage. Camilla runs a large equestrian facility and contributes insights into the needs, challenges, and conditions of the equestrian industry.
Independent in relation to the Company and its senior executives. Independent in relation to major shareholders.
Shareholding: 510,000
Member since: 2023
Mathias Uhlén
Member
Researches, among other things, proteins and
precision medicine, holds a
PhD in biotechnology, and is a professor at both Karolinska Institutet and the Royal Institute of Technology in Stockholm. Mathias has previously held board assignments for the National Committee for Biochemistry, HUPO International Antibody Initiative (HAI), and the European Federation Biotechnology (EFB), and currently holds a board assignment in the Swedish Research Council.
Independent in relation to the Company and its senior executives. Independent in relation to major shareholders.
Shareholding: 1,358,139
Member since: 2024
Lennart Johansson
Member
MBA from the Stockholm School of Economics with extensive experience from leading positions at Atlas Copco and Investor
(2006-2015). Previous board assignments: Gambro, Mölnlycke, Lindorff, SAAB, Hi3G, SOBI, and a number of unlisted
Life Science companies. Lennart also holds board assignments in Bonesupport, Chalmers Ventures, GoCo Development, and is a Senior Advisor to Patricia Industries.
Independent in relation to the Company and its senior executives. Independent in relation to major shareholders.
Shareholding: 2,140,246
Member since: 2023
Björn Odlander
Member
Founder and managing partner
at HealthCap. Björn previously
conducted research in biochemistry
focusing on inflammation at
Karolinska Institutet and was
Head of the Health Care Equity
Research Team at ABB Aros Securities. During his time at ABB Aros Securities, Björn also advised the management of several major pharmaceutical and
medical technology companies. Björn has extensive experience from numerous board assignments in listed and unlisted companies within the Life Science sector, including Q-Med AB, NicOx SA, Jerini AG, and Bonesupport.
Independent in relation to the Company and its senior executives.
Independent in relation to major shareholders.
Shareholding: 0
Member since: 2025
Mathias Uhlén
Member
Researches, among other things, proteins and
precision medicine, holds a
PhD in biotechnology,
and is a professor at both
Karolinska Institutet and the Royal
Institute of Technology
in Stockholm. Mathias has previously held board assignments for the National
Committee for Biochemistry, HUPO International Antibody Initiative (HAI), and the European Federation Biotechnology (EFB), and currently holds a board assignment in the Swedish Research Council.
Independent in relation to the Company and its senior executives. Independent in relation to major shareholders.
Shareholding: 1,358,139
Member since: 2024
Camilla Ramfelt McCarthy
Member
Marketing strategist and
business developer with extensive
experience in brand development and strengthening companies' market position, visibility, and growth through business-driven communication. Previously CEO and Creative Director at Ramfelt McCarthy advertising agency, and founder and editor-in-chief of the equestrian magazine Equipage. Camilla runs a large
equestrian facility and contributes insights into the needs, challenges, and conditions of the equestrian industry.
Independent in relation to the Company and its senior executives. Independent in relation to major shareholders.
Shareholding: 510,000
Member since: 2023
Lennart Johansson
Member
MBA from the Stockholm School of Economics with extensive experience from leading positions at Atlas Copco and Investor
(2006-2015). Previous board assignments: Gambro, Mölnlycke, Lindorff, SAAB, Hi3G, SOBI, and a number of unlisted
Life Science companies. Lennart also holds board assignments in Bonesupport, Chalmers Ventures, GoCo Development, and is a Senior Advisor to Patricia Industries.
Independent in relation to the Company and its senior executives. Independent in relation to major shareholders.
Shareholding: 2,140,246
Member since: 2023
Camilla Ramfelt McCarthy
Member
Marketing strategist and
business developer with extensive
experience in brand development and strengthening companies' market position, visibility, and growth through business-driven communication. Previously CEO and Creative Director at Ramfelt McCarthy advertising agency, and founder and editor-in-chief of the equestrian magazine Equipage. Camilla runs a large
equestrian facility and contributes insights into the needs, challenges, and conditions of the equestrian industry.
Independent in relation to the Company and its senior executives. Independent in relation to major shareholders.
Shareholding: 510,000
Member since: 2023
Björn Odlander
Member
Founder and managing partner
at HealthCap. Björn previously
conducted research in biochemistry
focusing on inflammation at
Karolinska Institutet and was
Head of the Health Care Equity
Research Team at ABB Aros Securities. During his time at ABB Aros Securities, Björn also advised the management of several major pharmaceutical and
medical technology companies. Björn has extensive experience from numerous board assignments in listed and unlisted companies within the Life Science sector, including Q-Med AB, NicOx SA, Jerini AG, and Bonesupport.
Independent in relation to the Company and its senior executives.
Independent in relation to major shareholders.
Shareholding: 0
Member since: 2025
Mathias Uhlén
Member
Researches, among other things, proteins and
precision medicine, holds a
PhD in biotechnology,
and is a professor at both
Karolinska Institutet and the Royal
Institute of Technology
in Stockholm. Mathias has previously held board assignments for the National
Committee for Biochemistry, HUPO International Antibody Initiative (HAI), and the European Federation Biotechnology (EFB), and currently holds a board assignment in the Swedish Research Council.
Independent in relation to the Company and its senior executives. Independent in relation to major shareholders.
Shareholding: 1,358,139
Member since: 2024
TECHNOLOGY
The fundamentals of our technology
The technology with fused recombinant proteins for the modern vaccines developed by Intervacc is based on nearly 20 years of research at Karolinska Institutet and the Swedish University of Agricultural Sciences, SLU.
The technology is complex, but here is a brief account of its basic principles, which form the platform for the vaccines Intervacc develops.
For a bacterium to be infectious, it must be able to attach to a tissue surface. This occurs through surface-localized bacterial proteins with a specific binding capacity (here called adhesins) to, for example, collagen, fibrin(ogen), fibronectin, and several other tissue structures.
Antibodies have two functions
The principle of Intervacc's vaccine development is to identify such surface-localized bacterial adhesins and produce them on a large scale using recombinant technology.
When used as vaccine components, antibodies are formed that have two main functions:
1) During an infection, the antibodies can bind to the adhesins, thereby hindering the bacterium's adhesion to the tissue. This blocks the infection process.
2) Antibodies that bind to surface-localized structures, such as adhesins, send a signal to white blood cells to internalize and kill the bacterium.
The proteins that constitute adhesins have, among other things, been identified through bioinformatic analysis of the DNA sequence from Streptococcus equi and can be compared with previously known virulence factors from, among others, Streptococcus pyogenes, a human pathogen similar to the one causing strangles.
Other proteins have also been identified whose function is important for the infection process, for example by impairing the horse's immune response. Antibodies against these have a neutralizing effect and deprive the bacterium of this “weapon”. This impairs the bacteria's immune defense capability.
Fusions at the DNA level
The effect of a vaccine increases significantly when several components are included in the vaccine. To still keep production costs down, Intervacc has created fusions at the DNA level so that several proteins are included in the same polypeptide. For example, Strangvac® contains three polypeptides, but these originate from eight different proteins.
Strains of S. equi isolated from strangles outbreaks in different parts of the world have a very high degree of similarity to each other. This means that only one version of the vaccine is needed to provide global coverage.
The same strategy for vaccine development has been chosen for vaccine candidates against Streptococcus suis and against Staphylococcus aureus.
Strangvac® vs. conventional vaccines
Conventional vaccines against bacterial infections generally consist of live attenuated or killed bacteria or of subcomponents, such as capsular polysaccharides and toxoids. When an attenuated bacterium is used as a vaccine, a subclinical infection occurs, often with mild or no symptoms, but antibodies are formed that have a protective capacity. However, there is a risk that the mild infection, caused by the vaccine strain, develops into a serious infection. Furthermore, it is possible that the generated immune response targets proteins that are less useful and therefore do not provide strong protective immunity.
When using conventional bacteria-containing vaccines against strangles, it has been reported that horses suffered from strangles infection instead of being protected. These strangles vaccines are used only to a limited extent. Intervacc has therefore opted out of this vaccination method.
Overall, Intervacc has the technology, expertise, and strategic collaborations that are required to take a project from research stage to finished product.
When a conventional vaccine with attenuated bacteria is used, there is a risk that the mild infection caused by the vaccine strain develops into a serious infection.
TECHNOLOGY
The fundamentals of our technology
The technology with fused recombinant proteins for the modern vaccines developed by Intervacc is based on nearly 20 years of research at Karolinska Institutet and the Swedish University of Agricultural Sciences.
The technology is complex, but here is a brief account of its basic principles, which form the platform for the vaccines Intervacc develops.
For a bacterium to be infectious, it must be able to attach to a tissue surface. This occurs through surface-localized bacterial proteins with a specific binding capacity (here called adhesins) to, for example, collagen, fibrin(ogen), fibronectin, and several other tissue structures.
Antibodies have two functions
The principle of Intervacc's vaccine development is to identify such surface-localized
bacterial adhesins and produce them on a large scale using recombinant technology.
When used as vaccine components, antibodies are formed that have two
main functions:
1) During an infection, the antibodies can bind to the adhesins, thereby hindering the bacterium's adhesion to the tissue. This blocks the infection process.
2) Antibodies that bind to surface-localized structures, such as adhesins, send a signal to white blood cells to internalize and kill the bacterium.
The proteins that constitute adhesins have, among other things, been identified through bioinformatic analysis of the DNA sequence from Streptococcus equi and can be compared with previously known virulence factors from, among others, Streptococcus pyogenes, a human pathogen similar to the one causing strangles.
Other proteins have also been identified whose function is important for the infection process,
for example by impairing the horse's immune response. Antibodies against these have a neutralizing effect and deprive the bacterium of this “weapon”. This impairs
the bacteria's immune defense capability.
Fusions at the DNA level
The effect of a vaccine increases significantly when several components are included in the vaccine. To
still keep production costs down, Intervacc has created fusions at the DNA level
so that several proteins are included in the same polypeptide. For example, Strangvac®
contains three polypeptides, but these originate from eight different proteins.
Strains of S. equi isolated from strangles outbreaks in different parts of the world have
a very high degree of similarity to each other. This means that only one version of the vaccine
is needed to provide global coverage.
The same strategy for vaccine development has been chosen for vaccine candidates against Streptococcus
suis and against Staphylococcus aureus.
Strangvac vs. conventional vaccines
Conventional vaccines against bacterial infections generally consist of live
attenuated or killed bacteria or of subcomponents, such as capsular polysaccharides and toxoids. When an attenuated bacterium is used as a vaccine, a subclinical infection occurs, often with mild or no symptoms, but antibodies are formed that have a protective capacity. However, there is a risk that the mild infection, caused by the vaccine strain, develops into a serious infection. Furthermore, it is possible that the generated immune response targets proteins that are less useful and therefore do not provide strong protective immunity.
When using conventional bacteria-containing vaccines against strangles, it has been reported that horses suffered from strangles infection instead of being protected. These strangles vaccines are used only to a limited extent. Intervacc has therefore opted out of this
vaccination method.
Overall, Intervacc has the technology, expertise, and strategic collaborations
required to take a project from research stage to finished product.
When a conventional vaccine with attenuated bacteria is used
there is a risk that the mild infection caused by the vaccine strain,
develops into a serious infection.
SCIENTIFIC
PUBLICATIONS
Publications and dissertations
Intervacc's employees have published and contributed to several publications in the vaccine field in reputable scientific journals.
Here is a compilation of publications that are relevant and linked to our main research areas – vaccines against infections caused by streptococci and staphylococci.
Publications and dissertations
Intervacc's employees have published and contributed to several publications in the vaccine field in reputable scientific journals.
Here is a compilation of publications that are relevant and linked to our main research areas – vaccines against infections caused by streptococci and staphylococci.
SCIENTIFIC
PUBLICATIONS
Peer-reviewed articles in international journals
Peer-reviewed articles in international journals
PUBLICATION
CATEGORY
TITLE
DATE
Microbial Genomics
Streptococcal evolution
Unravelling the unique essential genes of Streptococcus canis through transposon-directed insertion-site sequencing
No
https://www.microbiologyresearch.org/content/journal/mgen/10.1099/mgen.0.001701
Le Nouveau Praticien Veterinaire
Vaccine protection
Vaccination Against Strangles : Latest Scientific Advances
No
https://equine.le-nouveau-praticien-veterinaire.org/articles/npvequi/abs/2025/02/npvequi20250023/npvequi20250023.html
Animals
Vaccine field protection
Closing the Stable Door on Strangles: Serological Responses of Vaccinated Horses on a Farm Following the Arrival of a New Horse
Yes
https://www.mdpi.com/2076-2615/15/24/3584
Equine Veterinary Journal
Vaccine field protection
Reining in strangles: Absence of disease in horses vaccinated with a DIVA-compatible recombinant fusion protein vaccine, Strangvac, following natural exposure to Streptococcus equi subspecies equi
Yes
https://beva.onlinelibrary.wiley.com/doi/full/10.1111/evj.70125
Equine Veterinary Journal
Strangles biosecurity
Effectiveness of a screening protocol employed at a UK rescue centre to prevent introduction of strangles
No
https://beva.onlinelibrary.wiley.com/doi/10.1111/evj.70080
Five patent families
– so far
Intervacc has an active patent strategy, which means that patent and trademark applications are submitted in countries considered to have significant market potential or deemed key markets for the product in question.
The company currently owns 5 published patent families. These published patent families collectively include about 20 granted patents in force in various countries and several additional pending patent applications.
The primary purpose of the submitted patent applications is related to protecting the company's vaccine product Strangvac®.
In addition, the applications also describe the possibility of developing vaccine products to protect against diseases caused by Streptococcus zooepidemicus. The application documents thoroughly describe the various vaccine components, as well as their production and administration methods. Furthermore, the documents also contain examples where different combinations of vaccine formulations have been tested in animal studies, in both mice and horses.
The company has also registered the trademark for the vaccine Strangvac® and had it approved as a medicinal product name.
PATENTS
THE FIVE PUBLISHED PATENT FAMILIES ARE:
» Trivac, WO 2004/032957 A1, (priority 2002).
The patent is granted and valid in the USA until 2028.
» Penta/Septavacc, WO 2009/075646 A1, (priority 2007).
Patents are granted and valid in Europe until 2028 and the USA until 2031.
» Strangvac®, WO 2011/149419 A1, (priority 2010).
Patents are granted and in force in Europe, USA (US 9 795 664), Hong Kong, China, and Australia until 2031, with additional SPC protection granted or under processing in Europe until 2036.
» S. suis vaccine, WO 2017/005913 A1, (priority 2015).
Patent granted in the USA (US 11,155,585) and application is pending in Europe.
» S. suis vaccine, WO 2023/203238 A1, (priority 2023).
Application is pending in Europe, the USA, Canada, and China.
Five patent families
– so far
Intervacc has an active patent strategy, which means that patent
and trademark applications are submitted in countries considered to have significant market potential
or deemed key markets for the product in question.
The company currently owns 5 published patent families. These published patent families collectively include approximately 20 granted patents in force in various countries and several additional pending patent applications.
The primary purpose of the submitted patent applications is related to protecting the company's vaccine product Strangvac®.
In addition, the applications also describe the possibility of developing vaccine products to protect against diseases caused by Streptococcus zooepidemicus. The application documents thoroughly describe the various vaccine components, as well as their production and administration methods. Furthermore, the documents also contain examples where different combinations of vaccine formulations have been tested in animal studies, in both mice and horses.
The company has also registered the trademark for the Strangvac® vaccine and had it approved as a medicinal product name.
PATENTS
THE FIVE PUBLISHED PATENT FAMILIES ARE:
» Trivac, WO 2004/032957 A1, (priority 2002).
The patent has been granted and is valid in the USA until 2028.
» Penta/Septavacc, WO 2009/075646 A1, (priority 2007).
Patents have been granted and are valid in Europe until 2028 and the USA until 2031.
» Strangvac®, WO 2011/149419 A1, (priority 2010)
Patents have been granted and are in force in Europe, the USA (US 9,795,664), Hong Kong, China, and Australia until 2031, with additional SPC protection granted or pending in Europe until 2036.
» S. suis vaccine, WO 2017/005913 A1, (priority 2015)
Patent granted in the USA (US 11,155,585) and application is pending in Europe.
» S. suis vaccine, WO 2023/203238 A1, (priority 2023).
Application is pending in Europe, the USA, Canada, and China.
OUR PARTNERS
SLU, Uppsala
SLU is a leading Swedish university in Life Sciences with research and education in areas such as veterinary medicine, biology and animal health.
The long-standing research collaboration with SLU gives Intervacc access to a strong scientific environment and cutting-edge expertise in vaccine development.
An important network
Taking a vaccine from basic science research – via product development and clinical trials – to the market, requires multiple actors working together.
Over the years, Intervacc has built up an extensive and well-functioning network of partners to accommodate all aspects of development.
Intervacc's development is based on close collaborations with leading players in research, vaccine technology, clinical development, production, intellectual property rights and business consulting. Together, these partners form an international ecosystem of specialist expertise that supports the company's work from early research to finished product and commercialization. Intervacc values the long-term trust, knowledge and commitment that each partner contributes to the development of our modern vaccines for animal health.
KI, Stockholm
Karolinska Institutet is one of the world's leading medical universities and accounts for a significant portion of medical academic research in Sweden.
Through the long-standing research collaboration with Karolinska Institutet, Intervacc has access to an internationally prominent research environment and cutting-edge expertise in immunology and vaccine development.
Edinburgh, Scotland
Moredun Scientific is an internationally operating contract research organization with specialist expertise in animal health and veterinary product development.
Through the collaboration with Moredun, Intervacc has access to extensive experience in clinical studies, regulatory processes and the development of new vaccines.
Pamplona, Spain
3PBIOVIAN is a leading European CDMO providing end-to-end development and manufacturing services for biologics and advanced therapies.
The collaboration provides Intervacc with access to advanced manufacturing expertise and a scalable production platform that supports the long-term commercialization of Strangvac®.
Vitoria-Gasteiz, Spain
LIOF Pharma specializes in the aseptic manufacturing of injectable biological drugs.
The company is responsible for final formulation, aseptic vial filling and packaging of Strangvac®, ensuring an efficient and quality assured manufacturing process.
Uppsala
Novavax is an international biotechnology company with extensive experience in vaccine innovation and proprietary technology platforms.
Through the collaboration with Novavax, Intervacc has access to a proven adjuvant technology that helps enhance the immune response in Strangvac®.
Kentucky, USA
The Maxwell H. Gluck Equine Research Center is the only scientific institute in the United States with nearly all of the faculty conducting full-time research in equine health and diseases.
The Center is one of four leading institutes in the US responsible for conducting studies and tests that form an important part of the regulatory documentation for US market approval of Strangvac®.
Texas, USA
The College of Veterinary Medicine & Biomedical Sciences is ranked in the top five veterinary schools in the World and the faculty engage in cutting-edge clinical research that provide proactive solutions for animal health.
The College is one of four leading institutes in the US responsible for conducting studies and tests that form an important part of the regulatory documentation for US market approval of Strangvac®.
Iowa, USA
The Iowa State University College of Veterinary Medicine (ISU CVM) was the first state veterinary college in the United States and is dedicated to advancing the health and well-being of animals.
The College is also one of four institutions responsible for conducting the safety studies required for the regulatory approval of Strangvac® for the U.S. market.
Pennsylvania, USA
The research team at the University of Pennsylvania School of Veterinary Medicine (Penn Vet ) is a leader in the use of innovative technology to address veterinary issues of global significance.
The School is one of four leading institutes in the US responsible for conducting studies and tests that form an important part of the regulatory documentation for US market approval of Strangvac®.
Warwickshire, UK
Drayton Animal Health is a UK-based Contract Research Organisation (CRO) supporting the development and registration of veterinary medicines, feed additives and related products for foodproducing animals, including pigs, sheep, cattle and poultry.
Drayton Animal Health conducts clinical trials.
West Sussex, UK
Dechra is Intervacc's commercial partner for Strangvac® in Europe.
With a strong focus on veterinary medicine and an established presence in the European market, Dechra brings specialist expertise, market knowledge and an extensive distribution network to make Strangvac available to veterinarians and horse owners.
Stockholm
AWA is a leading intellectual property advisor with specialist expertise in patents, trademarks and IP strategy.
Through its partnership with AWA, Intervacc ensures strong protection for the company's innovations and technologies.
Stockholm
Cirio is a leading business law firm with broad expertise in corporate law, commercial contracts and transactions.
Cirio offers Intervacc qualified legal advice that supports the company's continued development and international business operations.
Stockholm
PwC is one of the world's leading companies in auditing, tax and business consulting with broad international expertise.
Through the collaboration with PwC, Intervacc receives qualified support in auditing and financial consulting that contributes to long-term sustainable corporate governance.
